Evidence map›Paper›PMID 25981118›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2015

Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.

Claudia Brockmann, Tobias Brockmann, Sabrina Dege, Catharina Busch, Norbert Kociok, Axel Vater, Sven Klussmann, Olaf Strauß, Antonia M Joussen

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Spatial distribution of CD115Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018
    Article
  9. Article
  10. Fit for the Eye: Aptamers in Ocular Disorders.Nucleic acid therapeutics · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Claudia BrockmannDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. claudia.brockmann@charite.de.
Tobias BrockmannDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Sabrina DegeDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Catharina BuschDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Norbert KociokDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Axel VaterNOXXON Pharma AG, Max-Dohrn-Strasse 8-10, 10589, Berlin, Germany.
Sven KlussmannNOXXON Pharma AG, Max-Dohrn-Strasse 8-10, 10589, Berlin, Germany.
Olaf StraußDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Antonia M JoussenDepartment of Ophthalmology, Charité - University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DENoxxon Pharma (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the influence of complement component C5a inhibition on laser-induced choroidal neovascularization (CNV) in mice using a C5a specific L-aptamer.

methodsIn C57BL/6 J mice CNV was induced by argon-laser, C5a-inhibitor (NOX-D20) was intravitreally injected in three concentrations: 0.3, 3.0, and 30 mg/ml. The unPEGylated derivate (NOX-D20001) was applied at 3.0 mg/ml; the vehicle (5 % glucose) was injected in controls. Vascular leakage was evaluated using fluorescence angiography, CNV area was examined immunohistochemically. Activated immune cells surrounding the CNV lesion and potential cytotoxicity were analyzed.

resultsCompared to controls, CNV areas were significantly reduced after NOX-D20 injection at a concentration of 0.3 and 3.0 mg/ml (p = 0.042; p = 0.016). NOX-D20001 significantly decreased CNV leakage but not the area (p = 0.007; p = 0.276). At a concentration of 30 mg/ml, NOX-D20 did not reveal significant effects on vascular leakage or CNV area (p = 0.624; p = 0.121). The amount of CD11b positive cells was significantly reduced after treatment with 0.3 and 3.0 mg/ml NOX-D20 (p = 0.027; p = 0.002). No adverse glial cell proliferation or increased apoptosis were observed at effective dosages.

conclusionsOur findings demonstrate that the targeted inhibition of complement component C5a reduces vascular leakage and neovascular area in laser-induced CNV in mice. NOX-D20 was proven to be an effective and safe agent that might be considered as a therapeutic candidate for CNV treatment. The deficiency of activated immune cells highlights promising new aspects in the pathology of choroidal neovascularization, and warrants further investigations.

Indexed as

AnimalsApoptosisAptamers, NucleotideCapillary PermeabilityChoroidal NeovascularizationComplement C5aDisease Models, AnimalFluorescein AngiographyGiant CellsImmunohistochemistryIntravitreal InjectionsLeukocytesMiceMice, Inbred C57BLSerine EndopeptidasesVitreous BodyAptamers, NucleotideComplement C5acomplement C5a-inhibitorsNOX-D20Serine EndopeptidasesC5a inhibitionComplement component C5aComplement systemIntravitreal injectionL-aptamerLaser-induced neovascularizationSpiegelmer

Identifiers

PMID25981118
OpenAlexW334386100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.